Saamya Biotech (India) IPO GMP History
Saamya Biotech (India) IPO has been listed on October 19, 2007 at a listing price of ₹17.5, against the issue price of ₹10 — a gain of ₹7.5 (+75%). The day-wise GMP trend below shows how grey market sentiment evolved from subscription to listing.
Saamya Biotech (India) IPO raised ₹15.01 Cr. through its IPO at a price band of TBA per share, with a lot size of 500 shares. The IPO was open for subscription from 25 Sep 2007 to 28 Sep 2007.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
GMP trend
Grey market premium sampled three times a day (11 AM, 5 PM, 10 PM). Last updated 12 Nov, 8:16 PM IST.
Day-wise GMP
The last reading of each day, newest first. Arrows compare with the previous day.
| Date | GMP | ↑↓ | % | Kostak | Sub. Sauda |
|---|---|---|---|---|---|
| No GMP history available yet. | |||||
Saamya Biotech (India) IPO dates
Key dates from opening to listing. Today is 12 November.
- Open 25 Sep 2007
- Close 28 Sep 2007
- Allotment 16 Oct 2007
- Refund/credit TBA
- Listing 19 Oct 2007
Saamya Biotech (India) IPO actual listing price
How the grey market's final call compared with the listing-day open.
| Issue price | ₹10 |
|---|---|
| Listing gain / loss | +₹7.5 per share |
| Listing date | 19 Oct, 2007 |
| Actual listing price | ₹17.5 (+75%) |
Is Saamya Biotech (India) IPO GMP reliable?
Grey market premium for Saamya Biotech (India) IPO should be interpreted with caution. The GMP is an unregulated, unofficial market not governed by SEBI. Here's how to read the current signal:
- 01Subscription rate matters: A high GMP paired with strong subscription — especially QIB (Qualified Institutional Buyer) oversubscription — is a more reliable bullish signal than GMP alone. Read our in-depth analysis: GMP vs Subscription Data — Which Predicts Listing Gains Better?
- 02Timing matters: GMP in the first 1–2 days of subscription is less reliable. GMP on the final subscription day and the day before listing tends to be the most accurate predictor.
- 03Grey market is thin: For smaller IPOs, even a handful of large orders can swing the GMP significantly. Treat low-volume GMP signals with extra caution.
- 04Cross-check before acting: Review the Saamya Biotech (India) IPO full review for a fundamentals-based assessment before making any grey market trades.
Saamya Biotech (India) IPO Kostak rate explained
Two ways the grey market trades an IPO application before listing.
The Kostak rate for Saamya Biotech (India) IPO was not available during the subscription period. Kostak is the fixed amount a grey market buyer pays for an IPO application regardless of allotment outcome.
The Subject to Sauda price was not available for this IPO. Subject to Sauda only applies if allotment is confirmed — the buyer pays a premium on top of the issue price per lot allotted.
Grey market trading is unofficial and unregulated by SEBI. Proceed with full awareness of the associated risks.
About Saamya Biotech (India) IPO
Saamya Biotech (India) Limited was incorporated on 13 August 2002 and set up as a 100% export oriented unit to make and trade chemicals, pharmaceuticals, drugs and intermediates. Its registered office is in Punjagutta, Hyderabad, and its promoters are Y. Manivardhan Reddy and Y. Sonia Reddy.
It planned to make only active pharma ingredients, namely daunomycin and hyaluronic acid.
The technology came from Biofin Laboratories of Italy and had been tested only at lab or pilot plant scale, not in large scale production.
The IPO was Rs 15.01 crore and was entirely a fresh issue at a fixed price of Rs 10, which was its face value. The money was for setting up its plant.
Frequently asked
What is the GMP of Saamya Biotech (India) IPO?
The current Grey Market Premium (GMP) of Saamya Biotech (India) IPO is not yet started or active in the market.
What is the Kostak Price of Saamya Biotech (India) IPO?
Kostak rate is the profit made by selling an IPO application before allotment. The current Kostak rate for Saamya Biotech (India) IPO is not available.
What is the Subject to Sauda Price of Saamya Biotech (India) IPO?
Subject to Sauda is the premium amount decided if the allotment is confirmed. The current Subject to Sauda rate is not available.
What was the actual listing price of Saamya Biotech (India) IPO?
Saamya Biotech (India) IPO listed on October 19, 2007 at ₹17.5, against the issue price of ₹10 — a gain of +75%.
How did the GMP of Saamya Biotech (India) IPO trend before listing?
The GMP of Saamya Biotech (India) IPO was stable in its final days before listing. View the day-wise table above for the complete GMP history.
Explore Saamya Biotech (India) IPO further
The grey market is one signal. Read it alongside the demand, the reviews and the filings before you decide.
It has listed — go back to the fundamentals.
Category-wise demand from QIB, NII and retail investors, updated through the day.
What brokers and analysts are saying about this issue, in one place.
Check with your PAN whether shares were credited to your demat account.
The grey market called it. Now check the fundamentals.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Read the grey market alongside the subscription book and the offer document before you apply.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
